Promising cocktail aims to shrink esophageal tumors before surgery
NCT ID NCT06576973
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether combining the immunotherapy adbelimumab with chemotherapy and the targeted drug apatinib can help shrink esophageal tumors before surgery. About 35 adults with resectable esophageal squamous cell carcinoma will receive four cycles of the drug combo, then undergo surgery. The main goal is to see how many patients have no cancer left in the removed tissue.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
adbelimumab (immunotherapy), albumin paclitaxel, carboplatin, apatinib
What this could lead to
If successful, this combination could become a new pre-surgery treatment to shrink tumors and reduce recurrence risk in esophageal cancer patients.
What could go wrong
This is a small, early-phase trial with only 35 participants, so results may not apply broadly. The combination also carries risks of side effects from chemotherapy and immunotherapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
2nd Affiliated Hospital, School of Medicine, Zhejiang University
RECRUITINGHangzhou, China, 310009, China
Contact Phone: •••-•••-•••• Email: •••••@•••••